BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC
Summary
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic CLK inhibitor targeting aberrant RNA splicingSAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- , a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced the closing of an $84 million Series B extension, bringing total capital raised by BlossomHill to $257 million to date. Commenced enrollment in the expansion cohorts of the Phase 1/2 SOLARA trial of BH-30643 (OMNI-EGFRTM inhibitor) in both targeted therapy-naive and pretreated patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Presented preliminary experience from the dose escalation portion of the Phase 1/2 SOLARA trial of BH-30643 (OMNI-EGFRTM inhibitor) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrating systemic and CNS anti-tumor activity across a variety of advanced EGFR-mutant NSCLCs with complex and difficult-to-treat resistance mutations. BH-30236 is currently being evaluated as a monotherapy or in combination with venetoclax in a first-in-human, Phase 1/1b dose escalation study in adult participants with relapsed or refractory acute myeloid leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). For additional information, including a list of study sites and how to enroll, please visit clinicaltrials.gov ( ).About BlossomHill TherapeuticsBlossomHill Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on designing and developing next-generation targeted therapies for cancer.